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S278 Poster Session IMethods: This retrospective cohort study evaluated patients who
underwent CBT at the Fred Hutchinson Cancer Research Center
(FHCRC) in Seattle, WA between 2006 and 2009. Data were col-
lected from patient medical records and the center’s clinical data-
bases. All IFI were classified as early (# 40 days post-transplant),
late (41-180 days) or very late (181-365 days), and pretransplant in-
fections were not included. Only proven or probable IFIs as defined
by standard criteria were analyzed. Incidence rates were determined
and a priori risk factors for IFI were assessed using chi squared or
Wilcoxon rank-sum analyses where applicable.
Results:A total of 103 CBT recipients were eligible for inclusion in
this study. Median age at time of transplant for the cohort was 30.4
years (interquartile range [IQR] 14, 48), and most patients under-
went myeloablative conditioning (71/103 [69%]) and received
a double cord transplant (88/103[85%]). Overall, 16 patients
(15.5%) developed 19 total IFIs (5 proven, 14 probable) within
the first year posttransplant. Following their primary episode 3 pa-
tients developed a second IFI due to a different fungal pathogen,
and 6 patients had a known pretransplant IFI which were excluded
from analyses. The median onset of first IFI was 65.5 days post-
transplant (IQR 28, 126). The cohort specific incidence rate of
IFI during the first year was 0.92 cases per 1000 patient days
(95% CI 0.56, 1.49). The majority of IFIs occurred during the
high risk early and late periods (both 9/19 [47%]). Invasive Aspergil-
lus was the most common IFI (12/19 [63%]) during the period of
observation, but others included Zygomycetes (3), Scopulariopsis
(1), Fusarium (1) and candidal species (2). Of the 16 patients that de-
veloped at least one IFI, 4/16 (25%) died as a direct result of their
fungal infection. Comparing CBT recipients who did and did not
develop IFI, graft-versus-host disease, time to engraftment, age,
conditioning regimen, and CMV serostatus were not associated
with the development of IFI.
Conclusions: Cord blood transplant recipients appear to be at high
risk for developing postransplant IFIs. Asmost IFIs occurred prior to
day 180 in this cohort, early prevention strategies and the use of
extended-spectrum azole prophylaxis may be needed in this
population.342
EVALUATIONOF A NOVEL VIRAL LOAD BASED SURVEILLANCE STRATEGY
FOR PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN HEMATO-
POIETIC CELL TRANSPLANTATION
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Introduction: Surveillance and preemptive therapy for CMV reac-
tivation is the most commonly used strategy to prevent CMV disease
in hematopoietic cell transplant (HCT) recipients. In 2007, our cen-
ter switched from a strategy using pp65 antigenemia testing with
treatment for any level of antigen, to one using quantitative PCR
tests (J. Clin. Microbiol. 42:p1142, 2004), with treatment thresholds
determined by each patient’s disease risk. We hypothesized that
this both sensitive and specific testing strategy would lead to earlier
diagnosis, thereby decreasing the incidence of CMV disease.
Methods: We retrospectively examined two cohorts of patients re-
ceiving their first allogeneic HCT who were either CMV seroposi-
tive (R+) or had a seropositive donor (D+/R-). Patients in the first
cohort (2002-2005, n5 703) received weekly antigen testing and an-
tiviral therapy was initiated for any positive test. Patients in the sec-
ond cohort (2007-2009, n 5 385) were tested by PCR weekly and
received therapy at a DNA level of. 500 copies/ml, unless receiving
$ 1mg/kg of prednisone or anti-T cell therapies in whom therapy
was initiated at a level . 100 copies/ml. Cord blood recipients
were excluded from analyses. Results were analyzed using multivari-
able Cox regression and competing risk regression models including
several pretransplant risk factors.
Results: In a multivariate model, PCR based testing resulted in
a similar overall 1 year mortality (adjusted HR 0.91, 95% CI 0.7-
1.1, p 5 0.38) to antigenemia testing. The cumulative incidence of
CMV disease by day 100 was also similar between the two groups
(aHR 1.25, 95% CI 0.7-2.3, p 5 0.48). Patients who were CMV
R+ pretransplant were more likely to develop CMV disease than
D+/R- patients (aHR 3.3, 95% CI 1.0-10.6, p 5 0.05). While theoverall rates of CMV disease were similar, PCR surveillance was
associated with more gastrointestinal disease and less pneumonia
(RR 0.36, 95% CI 0.08-0.86, p 5 0.02).
Conclusions: We have demonstrated that a preemptive treatment
strategy based on viral load and host risk factors resulted in similar
rates of CMV disease and overall survival compared to an antigene-
mia based strategy. The PCRbased strategywas associatedwith a de-
creased incidence of CMV pneumonia. Future studies are needed to
further examine the characteristics of gastrointestinal CMV disease
in seropositive patients that is not detected by blood based PCR
surveillance.343
SURVEY RESULTS OF IMMUNIZATION PRACTICES FOLLOWING HEMATO-
POIETIC STEM CELL TRANSPLANT AMONG CENTERS IN THE UNITED
STATES
Held, K.1, Smith, S.2, Shreve, N.3, Dalal, J.3, Liewer, S.4 1Children’s
Mercy Hospitals and Clinics, Kansas City, MO; 2The Johns Hopkins
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Vaccine immunity declines in recipients following hematopoietic
stem cell transplant (HSCT) placing patients at risk for significant
complications from vaccine-preventable diseases. An international,
collaborative group recently published recommendations to stan-
dardize revaccination of HSCT recipients. The purpose of this study
was to surveyHSCT centers within theUnited States to characterize
current vaccination practices.
Methods: A 25-question web-based survey was distributed six
months after the publication of updated guidelines to administrators
of HSCT centers throughout the United States registered with the
National Marrow Donor Program. All submitted survey responses
were included in the analysis.
Results: Forty-seven of the 124 eligible HSCT centers (38%) com-
pleted the survey. All survey responses were included in the analysis
although only 29 centers (62%) completed the full survey. Thirty-
one centers of 40 responding (78%) developed a standard operating
procedure which addressed revaccination and 38 programs (95%)
followed a standardized vaccination schedule. Approximately half
of the centers reimmunized autologous and allogeneic HSCT recip-
ients on the same schedule and a majority of centers (90%) altered
the vaccination schedule for patients receiving immunosuppression.
Nineteen of 37 responding centers (51%) routinely monitored im-
munologic markers prior to revaccination and thirteen of 29 centers
(45%) utilized the results to modify therapy. Following vaccine
administration, 8 of 37 responding centers (22%) obtained antibody
titers. The updated guideline included changes to administration of
the pneumococcal, diphtheria, tetanus, and acellular pertussis
vaccines and these practices were less consistent with the newly
published recommendations. Immunization practices that closely
followed the updated recommendations included vaccination with
theHaemophilus influenzae type b conjugate vaccine, inactivated polio
and hepatitis B vaccines.
Conclusions:Vaccination practices followingHSCT vary consider-
ably among programs within the United States despite the recent
publication of updated guidelines. Overall, the international recom-
mendations may help to standardize practice and improve patient
outcomes following HSCT. These findings highlight future educa-
tional opportunities for health care providers and the need for addi-
tional research.344
PREVENTION OF INVASIVE MOLD INFECTION POST ALLOGENEIC STEM
CELL TRANSPLANTATION (AlloSCT) IN PEDIATRIC RECIPIENTS USING
THE SEQUENTIAL COMBINATION OF LIPOSOMAL AMPHOTERICIN B (Am-
bisome) FOLLOWED BY MICAFUNGIN (Mycamine)
Small, T.N.1, El-Mallawany, N.1, Duffey, D.1, Bhatia, M.1, Garvin, J.1,
George, D.1, Satwani, P.1, Cairo, M.1,2,3 1Columbia University, Morgan
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Poster Session I S279Invasive mold infections (IMI) have been associated with signifi-
cant infectious relatedmortality post AlloSCT (Mehta et al ASBMT,
2010). We have previously demonstrated the safety and efficacy of
prophylactic liposomal amphotericin B (AMB) for 100 days post
AlloSCT in pediatric recipients (Roman/Cairo et al PBC, 2008).
Although AMB is effective for prophylaxis against IMI post Al-
loSCT, its association with nephrotoxicity and infusion related reac-
tions results in its discontinuation in. 10% of patients. Micafungin,
an echinocandin has been shown to be efficacious against both
Candida spp and Aspergillus spp with minimum toxicity and is
now approved for use as prophylaxis against invasive fungal infec-
tions in patients undergoing AlloSCT. (Pappas et al, 2009).
Methods: We conducted a prospective trial of administering pro-
phylactic AMB (3mg/kg/day) IV from d 0-44 then transitioning to
Micafungin (1mg/kg/day) IV at d 45 until d 100 if \ grade II
AGVHD at d +45. AGVHDprophylaxis were tacrolimus and myco-
phenolate mofetil (n 5 34) as we have previously described (Bhatia/
Cairo et al BBMT, 2009). Those who received CD-34 selected
PBSC (T-depleted) received tacrolimus only (n 5 15). Treatment
success was defined as prevention of IMI prior to day +100 post
AlloSCT.
Result: Median age: 8 yrs (2mo-23yr) Sex:14F, 35M Diagnose-
s:7ALL, 9AML, 6NHL, 1NBL, 6SAA, 1beta-Thal, 1MDS, 9SCD,
1FA, 1ALD, 2SCID, 1PNH, 1Atypical Wolmans, 3HLH. There
were 17CB donors (15-unrelated, 2-related), 16PBSC (15-unrelated,
1-related), 13RBM and 3URBM. The probability of developing $
grade II acute GVHD and extensive chronic GVHD was 12.2%
and 6%, respectively. There were no documented IMI within 100
days post transplantation. There were 7 documented invasive can-
dida infections (ICI). 4 ICI occurred while on AMB prior to switch-
ing to Micafungin, (mean of 21 days post AlloSCT), all infections
resolved in this cohort, the other 2 ICI occurred after switching to
Micafungin (mean of 30 days after switching) with one death due
to ICI. There were no reported side effects attributable to Micafun-
gin or discontinuation due to toxicity.
Conclusion: AlloSCT recipients are at high risk for both ICI and
IMI. Our preliminary data suggests that prophylaxis of AMB (D
0-44) and Micafungin (D 45-100) during the first 100 days post
AlloSCT is both safe and efficacious in preventing IMI. Larger ran-
domized studies are still needed to compare this combination to
other standard antifungal prophylaxis regimens.345
THE USE OF INTRAVENOUS ANTIBIOTICS AT THE ONSET OF NEUTROPE-
NIA IN PATIENTS RECEIVING HEMATOPOIETIC STEM CELL TRANS-
PLANTS: A ‘‘PRE-EMPTIVE’’ STRATEGY
Hamadah, A.1, Schreiber, Y.2, Toye, B.2, Doucette, S.3, McDiarmid, S.1,
Huebsch, L.1, Tay, J.1 1The Ottawa Hospital Blood and Marrow Pro-
gramme, Ottawa, ON, Canada; 2The Ottawa Hospital, Ottawa, ON,
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Background: Hematopoietic Stem Cell Transplant (HSCT) recip-
ients are at risk for fatal bacterial infections during the engraftment
period. Empirical antibiotic(s) at the onset of febrile neutropenia re-
main the standard of care. HSCT recipients began receiving intrave-
nous once daily ceftriaxone at the onset of neutropenia (neutrophils
\1.0) regardless of fever as part of The Ottawa Hospital Blood and
Marrow Outpatient Programme policy from Jan 2009; ‘‘pre-
emptive’’ approach. We examined the impact of this policy on
HSCT recipient outcomes.
Methods: A retrospective ‘‘before-after’’ study was conducted to
compare 2 cohorts [Jan 2008 - Dec 2008 (Empiric strategy) vs. Jan
2009 - Dec 2009 (Pre-emptive strategy)] of patients receiving
HSCT. Baseline characteristics between the groups were compared
with 2 sample tests. Categorical variables and continuous variables
were compared using Chi-squared and Wilcoxan rank-sum tests
respectively.
Results:There were 238 HSCTs performed between Jan 2008 and
Dec 2009 with 127 and 111 in the earlier and later cohorts respec-
tively. Baseline characteristics between the cohorts were similar.
Infection related mortality at 100 days after HSCT and during
the engraftment period were similar with a pre-emptive strategy
compared to an empiric strategy (7.2% vs 10.2%; p 5 0.41 and3.6% vs 7.1%; p 5 0.24) respectively. Further, there were no dif-
ferences in ICU admissions or length of hospital stay. Both micro-
biologically (MDI) and clinically documented infections (CDI)
were reduced (11.7% vs 29.1%;p 5 0.001 and 18.2% vs33.9%;p
5 0.007) with the pre-emptive strategy compared with an empiric
strategy. Importantly, recipients of autologous HSCT appear to
have a lower infection related mortality and reduced infection
related ICU admissions during the engraftment period with the
pre-emptive strategy compared to an empiric strategy (0% vs
6.8%; p 5 0.03 and 2.9% vs 12.2% p 5 0.04). The need for esca-
lation of antimicrobial treatments, resistance pattern of MDIs and
cost of antimicrobial treatment were not different between the two
groups.
Conclusions: The use of once daily intravenous ceftriaxone at the
onset of neutropenia in patients receiving HSCT is safe and effec-
tive particularly in patients receiving autologous HSCT. Further
studies are warranted to study the impact of this ‘‘pre-emptive’’
strategy.346
THE USE OF PSYCHOTROPIC MEDICATIONS IN PEDIATRIC STEM CELL
TRANSPLANT PATIENTS
Whitley, K.E.,Williams, T.,Muriel, A.C., Lehmann, L.E.,Duncan,C.N.
1Dana-Farber Cancer Institute, Boston, MA
The use of psychotropic medications during and following pedi-
atric hematopoietic stem cell transplant (HSCT) is not well de-
scribed. We performed a retrospective review of the prescription
of psychotropic medications during a two year period at our
institution. We report the use of the following medications from
admission to one year post-HSCT: fluoxetine, sertraline, fluvox-
amine, citalopram, trazodone, clonazepam, methylphenidate,
ziprazodone, apiprazole, risperidone, mirtazepine, bupropion,
escitalopram, olanzepine, and paroxetine. During this period 130
patients had a total of 152 transplants. Seventeen patients
(13.1%) were prescribed at least one of the medications investi-
gated. The majority of patients (55.6%) were prescribed more
than one medication. The medications used included: citalopram
(55.6%), risperidone (27.8%), methylphenidate (27.8%), clonaze-
pam (27.8%), trazodone (22.2%), mirtazepine (11.1%), escitalo-
pram (5.6%), and bupropion (5.6%). The timing of the initial
prescription of a psychotropic medication was prior to admission
(47.1%), during the initial transplant admission (29.4%), and 3-6
months post-HSCT (23.5%). Anxiety was the most common indi-
cation for starting a medication (30.3%) followed by depression
(18.2%), sleep disturbance (15.2%), mood stabilization (12.1%), fa-
tigue (9%), and other indication (15.2%). The median duration of
medication use was 116.4 days (range 3-374 days). Medications
were discontinued prior to one year post-HSCT due to symptom
improvement (38.5%), toxicity (7.7%), or patient refusal (11.5%).
34.6% were still on drug at one year post-HSCT and 7.7% died
prior to one year while receiving psychotropic medication. The
median age of patients who received psychotropic medications
was 13.5 years (4-19.6 years) compared to 7.4 years (0.5-22 years)
(p\ 0.0001) in patient who did not receive medications. There was
no significant difference in the sex, type of transplant, underlying
diagnosis, or presence of graft-versus-host disease between the
groups. Psychotropic medications are commonly prescribed in
this group of pediatric HSCT patients particularly in adolescents
and young adults. Further investigation is needed into the psychi-
atric needs of this high-risk population.347
USE OF PROCALCITONIN MEASUREMENTS TO DIAGNOSE INFECTION
IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
PATIENTS WITH FEVER
Kohashi, S., Nawa, Y., Matsubara, E., Nakase, K., Hara, M. Ehime
Prefectural Central Hospital, Matsuyama, Ehime, Japan
Background: Increase of CRP, WBC, and inflammatory cytokines
suggest the presence of inflammation but do not necessarily indicate
